Media stories about Chemed (NYSE:CHE) have been trending somewhat positive recently, according to Accern. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Chemed earned a news impact score of 0.10 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 45.2203485961405 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:
- Stolarsky-Mangine (clevelandjewishnews.com)
- DaVita (DVA) Surges: Stock Moves 13.6% Higher (zacks.com)
- Chemed Banks on Roto-Rooter Sales, Focuses on Vitas Revival (finance.yahoo.com)
- Align Technology Rides High on InvisAlign & Strategic Pacts (finance.yahoo.com)
- Chemed Corp. (CHE) VP Michael D. Witzeman Sells 1,000 Shares (americanbankingnews.com)
A number of analysts have recently commented on CHE shares. TheStreet raised shares of Chemed from a “c+” rating to an “a-” rating in a research report on Friday, October 27th. Zacks Investment Research raised shares of Chemed from a “hold” rating to a “buy” rating and set a $213.00 price objective on the stock in a research report on Wednesday, August 23rd. Royal Bank Of Canada reissued a “hold” rating and issued a $209.00 price objective on shares of Chemed in a research report on Friday, September 1st. KeyCorp reissued a “hold” rating on shares of Chemed in a research report on Friday, October 27th. Finally, ValuEngine lowered shares of Chemed from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $236.00.
Chemed (NYSE:CHE) last announced its quarterly earnings data on Thursday, October 26th. The company reported $2.15 EPS for the quarter, topping the Zacks’ consensus estimate of $2.00 by $0.15. The business had revenue of $417.40 million for the quarter, compared to analyst estimates of $414.34 million. Chemed had a net margin of 4.62% and a return on equity of 27.69%. The firm’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.73 earnings per share. equities analysts predict that Chemed will post 4.73 EPS for the current year.
The company also recently declared a quarterly dividend, which was paid on Monday, December 4th. Shareholders of record on Monday, November 13th were given a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a yield of 0.47%. The ex-dividend date was Friday, November 10th. Chemed’s dividend payout ratio (DPR) is currently 24.94%.
In other Chemed news, EVP Spencer S. Lee sold 1,000 shares of the company’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $228.45, for a total transaction of $228,450.00. Following the sale, the executive vice president now directly owns 36,809 shares of the company’s stock, valued at $8,409,016.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Patrick P. Grace sold 500 shares of the company’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $201.48, for a total transaction of $100,740.00. Following the sale, the director now directly owns 4,515 shares in the company, valued at $909,682.20. The disclosure for this sale can be found here. Insiders have sold 46,179 shares of company stock worth $10,729,699 over the last ninety days. Insiders own 4.90% of the company’s stock.
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with MarketBeat.com's FREE daily email newsletter.